Status:

RECRUITING

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Lead Sponsor:

Chinese Academy of Sciences

Collaborating Sponsors:

Peking Union Medical College Hospital

First Affiliated Hospital of Kunming Medical University

Conditions:

Hepatocellular Carcinoma (HCC)

Microvascular Invasion (MVI)

Eligibility:

All Genders

18-18 years

Brief Summary

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular ...

Detailed Description

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Early recurrence and long-term prognosis are closely linked to tumor aggressiveness. Microvascular invasion (...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years.
  • Confirmed diagnosis of hepatocellular carcinoma (HCC) according to the Chinese Clinical Practice Guidelines for Primary Liver Cancer.
  • Eligible for surgical intervention (hepatic resection or liver transplantation) according to the Chinese Clinical Practice Guidelines for Cancer, including stages Ia, Ib, and IIa.
  • Preoperative imaging examination performed within 1 month before surgery.
  • Availability of histopathological evaluation with documented microvascular invasion (MVI) status.

Exclusion

  • History of prior antitumor treatment, including preoperative surgical intervention, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), systemic therapy, or any other preoperative intervention.
  • Presence of major vascular invasion, bile duct invasion/thrombosis, extrahepatic metastasis, or lymph node involvement.
  • Diffuse hepatocellular carcinoma or tumor rupture with hemorrhage.
  • Lack of key data required for primary analysis.
  • Poor image quality that prevents reliable qualitative or radiomics analysis.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT07170345

Start Date

September 1 2025

End Date

September 1 2027

Last Update

September 12 2025

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, China

2

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

3

Zhujiang Hospital

Guangzhou, Guangdong, China

4

Fifth Affiliated Hospital, Sun Yat-Sen University

Zhuhai, Guangdong, China